Genome regions that do not for code for proteins are generally transcribed into long
non-coding RNAs. Growing evidence reveals that lncRNAs, defined as transcripts longer
than 200 nucleotides, are commonly deregulated in cervical malignancies. New sequencing
technologies have revealed a complete picture of the composition of the human transcriptome.
LncRNAs perform diverse functions at transcriptional, translation, and post-translational
levels through interactions with proteins, RNA and DNA. In the past decade, studies
have shown that lncRNAs participate in the pathogenesis of many diseases, including
cervical cancer. Hence, illuminating the roles of lncRNA will improve our understanding
of cervical cancer. In this work, we summarize the current knowledge on lncRNAs in
cervical cancer. We describe the emerging roles of lncRNAs in cervical cancer, particularly
in cancer progression, metastasis, treatment resistance, HPV regulation, and metabolic
reprogramming. The great promises of lncRNAs as potential biomarkers for cervical
cancer diagnosis and prognosis are also discussed. We discuss current technologies
used to target lncRNAs and thus control cancers, such as antisense oligonucleotides,
CRISPR-Cas9, and exosomes. Overall, we show that lncRNAs hold great potentials as
therapeutic agents and innovative biomarkers. Finally, further clinical research is
necessary to advance our understanding of the therapeutic value of lncRNAs in cervical
cancer.